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Abstract
Background
The efficacy of intermittent preventive treatment for malaria with sulfadoxine-pyrimethamine
(IPTp-SP) in pregnancy is threatened in parts of Africa by the emergence and spread of
resistance to SP. Intermittent screening with a rapid diagnostic test (RDT) and treatment of
positive women (ISTp) is an alternative approach.
Methods and Findings
An open, individually randomized, non-inferiority trial of IPTp-SP versus ISTp was con-
ducted in 5,354 primi- or secundigravidae in four West African countries with a low preva-
lence of resistance to SP (The Gambia, Mali, Burkina Faso and Ghana). Women in the
IPTp-SP group received SP on two or three occasions whilst women in the ISTp group were
screened two or three times with a RDT and treated if positive for malaria with artemether-
lumefantrine (AL). ISTp-AL was non-inferior to IPTp-SP in preventing low birth weight
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(LBW), anemia and placental malaria, the primary trial endpoints. The prevalence of LBW
was 15.1% and 15.6% in the IPTp-SP and ISTp-AL groups respectively (OR = 1.03 [95%
CI: 0.88, 1.22]). The mean hemoglobin concentration at the last clinic attendance before
delivery was 10.97g/dL and 10.94g/dL in the IPTp-SP and ISTp-AL groups respectively
(mean difference: -0.03 g/dL [95% CI: -0.13, +0.06]). Active malaria infection of the placenta
was found in 24.5% and in 24.2% of women in the IPTp-SP and ISTp-AL groups respec-
tively (OR = 0.95 [95% CI 0.81, 1.12]). More women in the ISTp-AL than in the IPTp-SP
group presented with malaria parasitemia between routine antenatal clinics (310 vs 182 epi-
sodes, rate difference: 49.4 per 1,000 pregnancies [95% CI 30.5, 68.3], but the number of
hospital admissions for malaria was similar in the two groups.
Conclusions
Despite low levels of resistance to SP in the study areas, ISTp-AL performed as well as
IPTp-SP. In the absence of an effective alternative medication to SP for IPTp, ISTp-AL is a
potential alternative to IPTp in areas where SP resistance is high. It may also have a role in
areas where malaria transmission is low and for the prevention of malaria in HIV positive
women receiving cotrimoxazole prophylaxis in whom SP is contraindicated.
Trial Registration
ClinicalTrials.gov NCT01084213
Pan African Clinical trials Registry PACT201202000272122
Introduction
Malaria infection during pregnancy (MIP) is a threat to both the pregnant woman and her
fetus. Currently recommended approaches for the control of MIP are provision of effective
treatment, insecticide treated bednets and intermittent preventive treatment with sulfadoxine-
pyrimethamine (IPTp-SP) given at each antenatal clinic (ANC) attendance after the first tri-
mester [1]. IPTp-SP is effective at preventing maternal anemia and low birthweight (LBW) in
areas where Plasmodium falciparum is susceptible to SP [2–5] but uptake of the intervention is
low in many communities [6] and its efficacy is threatened by the emergence of high level resis-
tance of P. falciparum to SP in some parts of Africa. There is evidence fromMalawi, Uganda,
the Democratic Republic of The Congo and Tanzania that IPTp-SP is losing its efficacy in pre-
venting the adverse effects of MIP [7–11] and it has been reported that in an area of north east-
ern Tanzania where P. falciparum strains frequently carry a 581G dhpsmutation in addition to
the quintuple dhfr/dhps SP resistance mutations, administration of IPTp-SP increases placental
parasitisation, inflammation in the placenta, fetal anemia and severe malaria in the infant [12–
14]. Mefloquine and the combination of azithromycin and chloroquine have been investigated
as alternatives to SP for IPTp but both were too poorly tolerated to be recommended for this
purpose [15,16]. There are currently no alternative drugs recommended for use in IPTp.
An alternative approach to IPTp-SP is screening women with a rapid diagnostic test (RDT)
during routine antenatal clinic (ANC) attendances and treating those who are positive with an
effective antimalarial combination, an approach termed intermittent screening and treatment
in pregnancy (ISTp). An initial trial of ISTp in Ghana showed that ISTp with artemether lume-
fantrine (ISTp-AL) was not inferior to IPTp-SP in preventing LBW and maternal anemia but
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its impact on placental malaria was not investigated in this study [17]. Here, we describe the
results of a larger, non-inferiority trial undertaken to investigate whether ISTp-AL is non-infe-
rior to IPTp-SP in preventing malaria infection of the placenta as well as being non-inferior in
the prevention of low birth weight (LBW) and anemia.
Methods
Study sites
The study was undertaken at sites in Burkina Faso, Ghana, Mali and The Gambia, where
malaria transmission is moderately high or high and seasonal. Resistance of P. falciparum to
SP is currently low in all four countries [18] (S1 Fig and S1 Table)
Ethics and registration
The trial protocol and amendments were approved by the ethics committees of each of the par-
ticipating African centers and by the ethics committee of the London School of Hygiene &
Tropical Medicine (S2 Table). A Data and Safety Monitoring Board (DSMB) reviewed the
overall conduct of the trial, which was monitored by independent clinical monitors, and
approved the analytical plans.
Trial registration. ClinicalTrials.gov (NCT01084213); Pan African Clinical trials Registry
(PACT201202000272122).
Recruitment procedure and randomization
Community sensitization and training of ANC and project staff preceded the start of the trial.
Primi- or secundigravidae who attended a study ANC between 31st May 2010 and 31st October
2011 were eligible to join the trial if they were between 16 and 30 weeks of gestation (assessed
by measurement of the symphysis-fundal height), permanent residents of the study area and
attending the ANC clinic for the first time. Exclusion criteria were a severe chronic infection,
including clinical AIDS, known allergy to SP, prior receipt of SP during the pregnancy or an
intention to leave the study area prior to delivery. HIV screening was conducted at first ANC
attendance in accordance with local practice and women who were HIV positive were referred
for further investigation and follow-up and were not recruited into the trial. Informed, written
consent was sought from all women who met the eligibility criteria. Women who consented to
join the trial were randomized using a pre-defined randomization procedure prepared in Stata
version 11 (StataCorp, College Station, Texas) by an independent statistician, employing per-
muted blocks of ten. Clinic staff who recruited women to the study were blind to the results of
the randomization process. The study was open-label but investigators, clinic staff recording
birth weight, laboratory staff and the project statistician were blind to treatment allocation.
Women were provided with a long-lasting insecticide treated bed net (Permanet 2, Wester-
gaard Fransen, Copenhagen) at their first ANC attendance and prescribed daily doses of fer-
rous sulfate (200mg) and folic acid (0.4mg) for the duration of their pregnancy.
Interventions and follow-up procedures
At the initial ANC visit, a blood sample was obtained for preparation of a blood film and filter
paper blood spot and for determination of the hemoglobin (Hb) concentration. Women in the
IPTp-SP arm then received their first treatment with SP (1500mg sulfadoxine/75mg pyrimeth-
amine)(UNICEF, Copenhagen) under direct observation whilst women in the ISTp-AL arm
were screened with a RDT and treated with artemether-lumefantrine (AL)(UNICEF, Copenha-
gen) for three days if positive. The first dose of AL was given under observation but subsequent
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doses were taken at home. A similar procedure was followed at the second and third routine
ANC visits, scheduled to occur at intervals of 4 to 6 weeks depending on the gestational age of
the woman at ANC booking. In three countries, two doses of SP were given whilst in Ghana
three doses were given in line with national guidelines. Women in the IPTp-SP group who had
observed fever and any symptoms suggestive of malaria were screened with an RDT and
treated with AL but not given SP on that occasion. At the fourth ANC visit, scheduled to occur
between 36–40 weeks of gestation, Hb concentration was measured and blood films were
taken. Women in either group who attended an ANC outside a scheduled visit with symptoms
judged by a routine member of the clinic staff to be suggestive of malaria were screened with a
RDT and treated with AL if positive. Adverse events were monitored passively throughout the
study period. Women were encouraged to deliver at a health facility where a peripheral blood
sample was collected. Following delivery, a placental smear and biopsy were obtained and the
birth weight of the baby was measured. Miscarriages, still births, neonatal deaths and congeni-
tal abnormalities were recorded. Women who delivered at home were visited as soon as possi-
ble after delivery and the baby weighed. If birth weight was not recorded within seven days of
delivery, this was not included in the according to protocol (ATP) analysis. Study women and
their babies were visited at home six weeks post partum for clinical assessment.
Laboratory methods
Blood films were read initially by two microscopists; discrepant films were read by a third
microscopist and a consensus result obtained using a standardized algorithm [19] as described
in S1 Text. Supplementary Methods. The First Response P. falciparumHRP2/pLDH RDT (Pre-
mier Medical Corporation Ltd., Mumbai, India) was used at each site throughout the study.
Hemoglobin concentrations were measured using 301 Hemocue analysers (HemoCue,
Anglom, Sweden). The methods used to obtain and process placental biopsies and to record
histological findings are described in the supplement. Blood spots obtained from study women
who were positive for P. falciparum at presentation were tested for mutations associated with
resistance to SP using a pooled sequencing approach described in the supplement [20].
Data management and statistical analysis
TeleForm (Version 10.4.1, Cardiff Software Inc., Vista CA), was used for electronic data cap-
ture. Following verification, scanned information was uploaded to a local database and also to
an anonymized database held at the London School of Hygiene & Tropical Medicine. Further
checks and cleaning were carried out by a central data management team who did not take part
in implementing the study. Three primary outcomes were defined: risk of LBW, maternal Hb
concentration prior to delivery and the prevalence of placental malaria. Sample size was calcu-
lated to give 90% power to exclude a clinically important difference in birth weight between
study groups, as described in the supplement. This resulted in a target sample size of 5000
women (1250 per center). Defining a non-inferiority margin a priori for LBW and placental
malaria (PM) was complicated by the fact the exact risk of these outcomes by center was not
known prior to the start of the trial; the odds ratio (OR) was used as a practical solution to this
problem [21]. For LBW, we specified an OR based on a consensus among the investigators that
a 4% risk difference in the prevalence of LBW would be clinically acceptable if the prevalence
was 20% in the IPTp-SP group i.e. the OR should be less than 1.263 (equating to a risk differ-
ence of 3.25% if the prevalence was 15%, and a 2.3% difference if the prevalence was 10%). For
PM, the margin was specified as a 5% excess of active malaria infection in the ISTp-AL group,
assuming a 25% prevalence of PM in the IPTp group (specified in terms of an OR less than
1.286). The non-inferiority margin for hemoglobin concentration at the final follow-up visit
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before delivery was specified to exclude a reduction of 0.2 g/dL in Hb concentration in the
ISTp-AL group relative to the IPTp group.
Two analysis plans were prepared covering clinical and laboratory findings respectively (S4
and S5 Texts) and both were approved by the DSMB which allowed the clinical findings to be
reviewed before all blood films and histological slides had been read. Stata version 13 (Stata-
Corp, College Station, Texas) was used for all analyses. Both according to protocol (ATP) and
modified intention to treat (ITT) analyses were performed in concordance with the CONSORT
guidelines for non-inferiority trials [22]. All women who had been randomized and contrib-
uted information on the outcome under consideration were included in the ITT analysis,
except that multiple births, still births and miscarriages were excluded from the analyses of
birth weight. Inclusion in the ATP analysis required that a woman had either received SP or
been tested with an RDT on at least two occasions and contributed information on the end-
point under consideration. For the primary outcomes, non-inferiority was formally investi-
gated by calculating the OR (for risk of LBW and placental malaria), or the difference in means
(for Hb concentration and birth weight), with adjustment for study centre as a covariate. Two-
sided 90, 95 and 99 per cent confidence intervals were calculated and compared to the pre-
specified non-inferiority margins (details are provided in the supplement). One-sided p-values
were used to assess evidence against the null hypothesis that ISTp-AL is inferior by the pre-
specified margin [23]. For secondary outcomes, 95% confidence intervals for differences
between groups were calculated but non-inferiority margins for these outcomes were not speci-
fied a priori. Rate differences for incidence of illness episodes were calculated using the method
of Xu et al [24].
The protocol, amendments and analyses plans are provided in the supplementary materials
(S2, S3, S4 and S5 Texts).
Results
Study population
The overall trial profile is shown in Fig 1 and profiles by center in S2, S3, S4 and S5 Figs; 6591
primi- or secundigravidae were screened for eligibility, 5354 of whom (81%) were enrolled and
randomly assigned to one of the two intervention groups. Baseline characteristics were well
matched overall (Table 1) and by center (S3 Table). Based on symphysis-fundal height, women
were enrolled at a mean of 20.6 weeks of gestation (median 20 weeks) of gestation; 97.5% of
women were enrolled before 28 weeks of gestation. Fifty-two percent of women in the ISTp-AL
group tested positive with an RDT and were treated with AL at some stage of their pregnancy,
35.6% once, 12.7% twice and 3.4% more than twice. The number of women who delivered at
home was similar in the two groups (7.43% and 8.82% in the IPTp-SP and ISTp-AL groups
respectively). Placental samples were obtained from 91.7% of the 4591 women who delivered
in a health centre. Women included in the ATP population for estimation of birth weight were
generally similar to those not included (S4 Table).
Birth weight
Birth weight was measured within 7 days of delivery for 4,659 of the 5,354 women enrolled
(87%), 4,391 of whom were included in the ATP analysis. Risk of LBW was 15.1% and 15.6%
in the IPTp-SP and ISTp-AL groups respectively (Table 2). Unadjusted and adjusted ORs for
LBW in the ATP population were 1.03 (95% CI: 0.88, 1.22), and 1.03 (0.87, 1.22) respectively
(Fig 2) (S5 Table). The ORs for the 4738 women included in the ITT analysis were very similar:
1.05 (95%CI: 0.90, 1.23) (S5 Table). The 95% confidence intervals for these ORs all exclude the
pre-specified non-inferiority margin of 1.263, with one-sided p-values assessing the null
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hypothesis of inferiority of0.01. Analysis by country showed a similar pattern of non-inferi-
ority in prevention of LBW (S6 Table).
Mean birth weight was 2,866 g (SD 418 g) and 2,838 g (SD 438 g) in the IPTp-SP and ISTp-
AL groups respectively. The distribution of birth weights was very similar between the inter-
vention groups both overall (Fig 3) and by country (S6 Fig). The mean differences in birth
Fig 1. CONSORT Flow Diagram. Footnote: LTFU—Lost to follow-up. * two of these 3 deaths occurred on the day of delivery. $ missed subsequent visit but
remained in follow up. # numbers shown at post-partum include 8 and 9 women in IPTp-SP and ISTp-AL groups respectively who were not seen at delivery
but who remained in follow-up.
doi:10.1371/journal.pone.0132247.g001
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weight between study groups (ISTp-AL—IPTp-SP) were: unadjusted ATP, -26.6 g (95% CI:
-51.8, -1.5); adjusted ATP, -26.0 g (95% CI: -51.1, -0.9); ITT, -27.7 g (95% CI: -52.8, -2.6). The
two sided 95% confidence interval (equivalent to a one-sided 97.5% CI) overlaps the noninfer-
iority margin for both the ATP and adjusted ATP analyses. However, the two-sided 90% CI
(equivalent to a one-sided 95% CI) excluded the non-inferiority margin of 50g in all three sets
of analyses (Fig 2). One-sided p-values, indicating moderate evidence against the null hypothe-
sis of inferiority were 0.034, 0.031 and 0.041 for ATP, adjusted ATP and ITT analyses respec-
tively. The difference in mean birth weight between IPTp-SP and ISTp-AL groups in Ghana,
where IPTp-SP and ISTp-AL were both delivered on three occasions, was very small and simi-
lar to that seen in other countries (S7 Fig).
Hemoglobin concentration
Mean Hb concentration at the last clinic attendance before delivery was 10.97 g/dL (SD 1.35 g/
dL) and 10.94 g/L (SD 1.38 g/dL) in women in the IPTp-SP or ISTp-AL groups respectively.
The distribution of Hb concentrations was very similar in the two groups overall (Fig 3) and at
Table 1. Baseline characteristics of the study participants.
IPTp-SP ISTp-AL Total
Age group Mean (SD) 20.4 (3.21) 20.4 (3.43) 20.4 (3.32)
Median (IQR) 20 (18, 22) 20 (18, 22) 20 (18, 22)
No. % No. % No. %
Gravidity primi- 1450 54.4 1476 55.4 2926 54.9
secundi- 1214 45.6 1189 44.6 2403 45.1
Education None 1213 45.6 1210 45.7 2423 45.6
Basic 1104 41.5 1065 40.2 2169 40.8
Secondary 304 11.4 337 12.7 641 12.1
Tertiary 42 1.58 36 1.36 78 1.47
Religion Christian 752 28.2 777 29.3 1529 28.8
Islam 1849 69.3 1823 68.7 3672 69.0
Traditional 41 1.54 31 1.17 72 1.35
none/other 25 0.94 21 0.79 46 0.86
Marital Status Married 2433 91.4 2408 90.9 4841 91.2
Not married 228 8.57 242 9.13 470 8.85
Slept under treated net last night yes 1555 58.8 1544 58.8 3099 58.8
no 1090 41.2 1084 41.3 2174 41.2
IRS in sleeping room yes 135 5.38 123 4.95 258 5.17
in last 6 months no 2373 94.6 2364 95.1 4737 94.8
Malaria parasitemia
Positive (by microscopy) 808/2609 30.97 807/2628 30.71 1615/5237 30.84
Geometric mean density 1345.9 1297.8 1321.6
(95% CI) (1222.9, 1481.2) (1179.0, 1428.6) (1235.0, 1414.2)
Hemoglobin at ﬁrst visit <5 5 0.19 4 0.15 9 0.17
5–7.99 167 6.24 174 6.51 341 6.38
8–10.99 1566 58.5 1546 57.9 3112 58.2
11+ 937 35.0 947 35.5 1884 35.2
Mean (SD) 10.31 (1.51) 10.34 (1.55) 10.32 (1.53)
CI; Conﬁdence interval; IRS, indoor residual spraying of insecticide; IQR, inter-quartile range; SD, standard deviation.
doi:10.1371/journal.pone.0132247.t001
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each site (S8 Fig). The 95% confidence intervals for the mean difference in Hb concentrations
for both unadjusted and adjusted ATP, and ITT analyses excluded the non-inferiority margin
of -0.2g/dL: unadjusted ATP, -0.03g/dL (95% CI: -0.13, 0.06); adjusted ATP, -0.01g/dL (95%
CI: -0.11, 0.08); ITT, -0.02g/dL (95% CI: -0.11, 0.07). The 99% confidence intervals also
excluded this non-inferiority margin (Fig 2). The prevalence of anemia (Hb< 11.0 g/dL) and
severe anemia (Hb< 5 g/dL) at the final follow-up visit before delivery and at delivery were
similar in each study group (Table 2), with the confidence interval for the OR overlapping one
in all cases.
Placental malaria
Interpretable placental biopsy specimens were obtained from 71.6% and 70.6% of women in
the IPTp-SP or ISTp-AL groups respectively. The characteristics of women from whom a pla-
cental sample was obtained and of those from whom it was not because they had delivered at
home were very similar (S7 Table). The prevalence of active malaria infection of the placenta
was very similar in the IPTp-SP and ISTp-AL groups overall: 24.5% and 24.2% respectively
(OR 0.95 [95% CI 0.81, 1.12]) (Table 3). ISTp-AL was thus non-inferior to IPTp-SP in prevent-
ing active placental malaria in all analyses and at all levels of confidence (Fig 2). Acute infec-
tions were slightly more frequent in the IPTp-SP group than in the ISTp-AL group whilst the
opposite trend was observed for chronic infections but neither of these differences was
Table 2. Risk of low birth weight and anemia by intervention group.
Burkina Gambia Ghana Mali Overall
IPTp-SP ISTp-AL IPTp-SP ISTp-AL IPTp-SP ISTp-AL IPTp-SP ISTp-AL IPTp-SP ISTp-AL
Number of women 599 613 484 461 524 552 564 573 2183 2208
Low birth weight
No. Low birth weight 108 108 72 60 86 97 64 79 330 344
% low birth weight 17.9 17.5 14.9 13.0 16.4 17.4 11.4 13.8 15.1 15.6
Odds Ratio (95% CI) 0.98 (0.73, 1.32) 0.86 (0.59, 1.24) 1.08 (0.79, 1.49) 1.25 (0.88, 1.78) 1.03 (0.88, 1.22)
Anemia
Number assessed at fourth visit 506 546 324 318 256 272 448 464 1534 1600
No. with Hb < 11 g / dL 246 270 202 179 135 149 176 205 759 803
% Hb < 11 g / dL 48.6 49.5 62.4 56.3 52.7 54.8 39.3 44.2 49.5 50.2
Odds Ratio (95% CI) 1.03 (0.81, 1.32) 0.78 (0.57, 1.07) 1.09 (0.77, 1.53) 1.22 (0.94, 1.59) 1.03 (0.90, 1.19)
No. with Hb < 8 g / dL 10 13 13 14 2 5 1 5 26 37
% Hb < 8 g / dL 1.98 2.38 4.01 4.40 0.78 1.84 0.22 1.08 1.69 2.31
Odds Ratio (95% CI) 1.21 (0.53, 2.78) 1.10 (0.51, 2.38) 2.38 (0.46, 12.4) 4.87 (0.57, 41.8) 1.39 (0.84, 2.32)
Number assessed at delivery 490 523 280 272 217 239 437 450 2170 2220
No. with Hb < 11 g / dL 177 203 116 120 91 100 95 112 801 863
% Hb < 11 g / dL 36.1 38.8 41.4 44.1 41.9 41.8 21.7 24.9 36.9 38.9
Odds Ratio (95% CI) 1.12 (0.87, 1.45) 1.12 (0.80, 1.56) 1.00 (0.69, 1.45) 1.19 (0.87, 1.63) 1.11 (0.95, 1.30)
No. with Hb < 8 g / dL 7 11 4 8 0 1 2 1 33 41
% Hb < 8 g / dL 1.43 2.10 1.43 2.94 0 0.42 0.46 0.22 1.52 1.85
Odds Ratio (95% CI) 1.48 (0.57, 3.86) 2.09 (0.62, 7.03) - 0.48 (0.044, 5.36) 1.58 (0.79, 3.18)
CI; Conﬁdence interval. Numbers shown are for the according to protocol (ATP) population. The odds ratio is given as the measure of effect because the
non-inferiority margin for the OR (1.263 for low birth weight) can be deﬁned independently of the underlying prevalence. The pooled estimate of the odds
ratio is also not affected by changes in prevalence in the different sites as the risk difference or risk ratio would be. Outcomes for low birth weight split by
gravidity are given in S5 Table.
doi:10.1371/journal.pone.0132247.t002
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statistically significant (Table 3). Moderate or abundant pigment in fibrin was observed more
frequently in samples from women in the ISTp-AL than in the IPTp-SP group (Table 3) but
differences between groups were small (P = 0.076). Intervillous inflammation of varying
degrees of severity was seen in a similar proportion of samples from women in each group. Pla-
cental blood smears were positive in 128/1,815 (7.05%) of women in the IPTp-SP group and in
157/1,858 (8.45%) of women in the ISTp-AL group (OR 1.22 [95% CI: 0.95, 1.55], p = 0.11).
Although the prevalence of malaria infection of the placenta varied by country, results obtained
in the IPTp-SP and ISTp-AL groups were similar in each country (S8 Table) and by gravidity
(S9 Table).
Secondary outcomes
Unscheduled clinic visits between routine ANC contacts were more frequent among women in
the ISTp-AL group (1204 visits) than in those in the IPTp-SP group (988 visits) (p = 0.001).
Common complaints were headache (50.3% of visits), fever (32.1%), abdominal pain (27.1%)
Fig 2. Non-inferiority plots for primary outcomes andmean birth weight. The figures show two-sided 90%, 95% and 99% confidence intervals (largest
to smallest vertical bars, respectively), equivalent to one-sided 95%, 97.5% and 99.5% confidence intervals. The dashed blue vertical line indicates the non-
inferiority margin. ATP, according to protocol population (adjusted for site); adjusted, ATP population adjusted for site, gravidity, age group, gestational age,
ITN use and socio-economic status; ITT, intention to treat, (adjusted for site). Numbers included in the analyses and numeric values of the estimates are
provided in the supplement (S4 Table).
doi:10.1371/journal.pone.0132247.g002
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and waist pain (14.6%); headache and chills were reported more frequently by women in the
ISTp-AL than in those in the IPTp-SP group. A RDT was done due to suspicion that a woman
might have malaria more frequently in the ISTp-AL group (977 occasions) than in the IPTp-
SP group (680 occasions) and the test was positive on 439 (44.9%) and 235 (34.6%) occasions
respectively. The incidence at unscheduled visits of malaria parasitemia, confirmed by micros-
copy, in the two groups was 124.9 (95% CI 111.4, 139.7) and 75.2 (95% CI: 64.7, 87.0) per 1000
pregnancies, a rate difference 49.4 per 1000 pregnancies (95% CI 30.5, 68.3)(p<0.001). Geo-
metric mean parasite density was similar in the IPTp-SP and ISTp-AL groups (9741.6 and
11302.0/μl per μl respectively) (p = 0.459). Nearly all malaria infections were mild (95.2% and
93.4% and in the ISTp-AL and IPTp-SP groups respectively). Only 22 women with a positive
blood slide were admitted to hospital, 13 in the ISTp-AL and 9 in the IPTp-SP groups
respectively.
Fig 3. Distribution of birth weight (A) and hemoglobin concentration (B) at fourth ANC visit by
intervention group. Birth weight distributions were estimated using data from 2183 women in the IPTp-SP
group and from 2208 women in the ISTp-AL group. Hemoglobin distributions utilise data from 1534 women in
the IPTp-SP group and from 1600 women in the ISTp-AL group.
doi:10.1371/journal.pone.0132247.g003
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The prevalence of malaria parasitemia in the IPTp-SP and ISTp-AL groups was very similar
at the final ANC visit (89/1487 [5.99%] vs 106/1569 [6.76%]), at delivery (171/2030 [8.42%] vs
206/2104 [9.79%]) and post-partum (135/2065 [6.54%] vs 137/2110 [6.49%]) giving ORs of
1.13 (95% CI: 0.84, 1.52), 1.18 (95% CI 0.95, 1.47) and 0.98 (95% CI 0.77, 1.26), respectively.
Geometric mean parasite densities/μl in the IPTp-SP and ISTp-AL groups were also similar at
each of these contacts: 1303.4 vs. 1872.6, p = 0.161; 2750.5 vs. 3398.5, p = 0.359 and 380.4 vs.
524.5, p = 0.091 at final ANC, delivery and post-partum, respectively.
Parasites obtained at enrolment were genotyped for markers of SP resistance. The dhps
K540Emutation, which predicts the dhfr-dhps quintuple mutant haplotype that confers a high
Table 3. Prevalence of placental malaria by study group.
IPTp ISTp-AL
N % N % Odds ratio (95% CI)
Placental histology N = 1672 N = 1690
Active infection (acute or chronic)1 409 24.5 409 24.2 0.95 (0.81, 1.12)
Infection type N = 1672 N = 1689
Acute infections 207 12.4 177 10.5 0.81 (0.65, 1.00)
Chronic infections 202 12.1 231 13.7 1.13 (0.91, 1.39)
Placental blood smear N = 1815 N = 1858
Negative 1687 93.0 1701 91.6
Positive 128 7.05 157 8.45 1.22 (0.95, 1.55)
Intervillous inﬂammation N = 1685 N = 1704
<5 per high powered ﬁeld 1449 86.0 1432 84.0 0.87 (0.72, 1.05)
5–10 186 11.0 214 12.6 1.15 (0.93, 1.42)
10–25 38 2.26 38 2.23 0.96 (0.61, 1.52)
>25 12 0.71 20 1.17 1.62 (0.79, 3.32)
Among those without active infection
Pigment in ﬁbrin2 N = 1262 N = 1276
None 441 34.9 387 30.3 0.82 (0.68, 0.99)
Mild 365 28.9 379 29.7 1.02 (0.86, 1.22)
Moderate 447 35.4 498 39.0 1.15 (0.96, 1.37)
Abundant 9 0.71 12 0.94 1.29 (0.54, 3.09)
Pigment in macrophages2 N = 1259 N = 1277
None 1096 87.1 1045 81.8 0.68 (0.54, 0.85)
Mild 42 3.34 59 4.62 1.37 (0.91, 2.06)
Moderate 114 9.05 163 12.8 1.44 (1.11, 1.87)
Abundant 7 0.56 10 0.78 1.38 (0.52, 3.64)
Pigment in ﬁbrin and macrophages2 N = 1260 N = 1277
None 1098 87.1 1046 81.9 0.68 (0.54, 0.85)
Mild 41 3.25 58 4.54 1.38 (0.92, 2.08)
Moderate 114 9.05 163 12.8 1.44 (1.11, 1.87)
Abundant 7 0.56 10 0.78 1.38 (0.52, 3.64)
Numbers shown for the according to protocol (ATP) population.
1 Co-primary outcome for study. Odds ratios are adjusted for site, Acute infection: Infected maternal erythrocytes and no or minimal pigment. Chronic
infection: Infected maternal erythrocytes and moderate or abundant pigment.
2 Data for presence of pigment are shown only for children without active malaria infection. Numbers available for each analysis are shown, as complete
information on malaria infection, inﬂammation and pigment in different locations was not available for all samples: seven women were missing data on
pigment in ﬁbrin, 28 on pigment in macrophages, and six on inﬂammation.
doi:10.1371/journal.pone.0132247.t003
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risk of SP failure, [25] was absent in Burkina Faso, Ghana, Gambia, and San, Mali, and present
at< 1% in Kita, Mali (S10 Table). Each site harbored moderate frequencies of dhfrmutations,
but neither the dhfr I164L nor dhps A581Gmutations were detected. These findings are sup-
ported by a parallel study in two of the study sites (Burkina Faso and Mali) which showed a
high level of clinical efficacy of SP in asymptomatic, pregnant women [26].
Six women died during the study, five in the IPTp-SP group and one in the ISTp-AL group.
Deaths in the IPTp-SP group were attributed to postpartum haemorrhage (2), severe malarial
anemia (1), septicemia (1) and eclampsia (1). The only death in the ISTp-AL group was attrib-
uted to placenta praevia. The number of miscarriages, pre-term births, still births, babies small
for gestational age and perinatal deaths were similar in each intervention group (Table 4).
Thirty-three congenital abnormalities were detected, 15 in the IPTp-SP group and 18 in the
ISTp-AL group (S11 Table).
No drug related serious adverse event was recorded. Women in the IPTp-SP complained of
dizziness, sleeplessness, weakness, nausea and vomiting since their last ANC visit more fre-
quently than women in the ISTp-AL group and associated this with taking SP.
Discussion
Intermittent screening and treatment was non-inferior to IPTp-SP in preventing LBW, mater-
nal anemia and placental malaria, the primary trial end-points, in four countries where P. fal-
ciparum is still sensitive to SP and IPTp-SP is still likely to be highly effective. However, the
incidence of clinic visits between routine ANC attendances with symptoms accompanied by
malaria parasitemia was higher in women in the ISTp-AL than in the IPTp-SP group. Nearly
all these infections were mild, with very few hospital admissions in either group, but the signifi-
cance of this finding needs further evaluation.
Strengths of this trial are that it was large and powered to exclude a modest difference in
LBW, anemia or placental malaria and that similar findings were recorded at each site, which
differed in their intensity of malaria transmission, strengthening the general application of the
study’s findings. Limitations of the study include lack of a complete set of observations for all
women, although completeness was similar between intervention groups. At the time at which
this study was conducted, the WHO recommended that pregnant women should receive at
least two treatments with SP during pregnancy and, in three of the study countries (Burkina
Table 4. Adverse birth outcomes and deaths.
IPTp IST Odds Ratio (95% CI)
Adverse birth outcomes No. % No. %
Congenital abnormality1 15 0.60 18 0.72 1.20 (0.60, 2.39)
Small for gestational age 392 23.2 432 25.3 1.12 (0.95, 1.31)
Miscarriage 15 0.60 18 0.72 1.19 (0.60, 2.37)
Preterm birth 173 7.05 177 7.20 1.04 (0.83, 1.29)
Stillbirths 76 3.06 84 3.39 1.12 (0.82, 1.53)
Deaths
Perinatal death 115 4.62 122 4.92 1.07 (0.82, 1.39)
Maternal death 5 0.19 1 0.04 0.20 (0.02, 1.71)
CI; Conﬁdence interval.
1 Details of the congenital abnormalities are given in the supplement, S10 Table. Small for gestational age was deﬁned as birth weight less than the 10th
centile of the nomogram deﬁned by Landis et al.[28]
doi:10.1371/journal.pone.0132247.t004
Screening and Treatment for Malaria in Pregnancy
PLOS ONE | DOI:10.1371/journal.pone.0132247 August 10, 2015 12 / 17
Faso, Mali and The Gambia), national practice was to give only two doses. In these countries
some women in the ISTp-AL group were screened for malaria during a third routine ANC visit
whilst, following national policy, those in the IPTp-SP group did not receive a third dose of
IPTp-SP. However, in Ghana, where SP administration and RDT screening were each con-
ducted on three occasions, similar results were obtained to those at the other sites. This sug-
gests that this limitation has not affected the overall results of the trial.
It is possible that RDTs were used more readily in women from the ISTp-AL than in those
from the IPTp-SP group who presented between routine clinics, although we have no evidence
that this was the case. If this was so, this could have contributed to the higher frequency with
which parasitaemia was detected at unscheduled visits among women in the ISTp-AL group.
Testing more women between routine visits might also benefit the outcomes of pregnancy if it
resulted in additional infections being detected. The potential impact of introducing ISTp on
overall practice in the antenatal clinic is an important issue and one which is currently being
investigated.
Intermittent screening and treatment was well accepted by pregnant women and clinic staff,
as noted previously [27]. However, ISTp, whether with AL or other regimens, is likely to be
more costly than IPTp-SP because the cost of an RDT is higher than the cost of a treatment
with SP, and more complex to administer. These drawbacks need to be balanced against the
non-financial benefits achieved from sparing a large number of women unnecessary adminis-
tration of a drug during pregnancy and the mild side effects associated with taking SP. Detailed
information on the costs, cost-effectiveness and acceptability of ISTp-AL during this trial will
be reported subsequently.
Under what conditions might ISTp prove to be a valuable approach to the control of malaria
in pregnancy? Firstly, there are currently no grounds to suggest that it should replace IPTp-SP
in areas where P. falciparum remains sensitive to SP and every effort needs to be made to
increase coverage with IPTp-SP in such areas. However, in areas of eastern and southern Africa
where P. falciparum has become highly resistant to SP, ISTp-AL may be superior to IPTp-SP;
this is being investigated in on-going trials in Kenya and Malawi. This study has shown that
ISTp-AL is a potential future option for control of malaria in pregnancy in West Africa if resis-
tance to SP continues to increase in this part of the continent, as seems likely. Secondly, the
level of malaria transmission below which IPTp-SP is no longer useful is not known and, con-
sequently, there is a reluctance to stop IPTp-SP in low transmission settings without an alterna-
tive. In such situations, both within and outside sub-Saharan Africa, ISTp-AL could be an
effective alternative until malaria is no longer a significant threat. In addition, routine screening
at ANC clinics would provide valuable, local information on changes in the prevalence of
malaria associated with environmental changes or control activities. A third potential use of
ISTp-AL is in HIV infected pregnant women receiving cotrimoxazole prophylaxis, in whom
IPTp-SP is contraindicated. Finally, ISTp-AL could be used in the first trimester of pregnancy
when IPTp-SP is not recommended. The results of this trial show that ISTp-AL is a potentially
valuable approach to the control of malaria in pregnancy in some circumstances but more
research is needed to determine its place among the limited number of options available to con-
trol malaria in pregnancy.
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